Author:

  • All
  • --
  • ---
  • -2022
  • 2022-2
  • 2022-2-2-2
  • 2022-deltia-tipoy
  • 2022-deltia-tipoy-2-2
  • 2022-deltia-tipoy-2-2-2-2
  • 2023-deltia-typou
  • 2023-deltia-typou-2-2
  • 2024
  • 257-2
  • 257-2-2-2
  • 266-2
  • Announcements
  • Announcements 2025
  • Consolidated Financial Results
  • deltia-tipoy
  • deltia-tipoy-2-2
  • deltia-tipoy-2-2-2-2
  • Distribution of Divident
  • Events
  • FAQ
  • General Meetings and Corporate Actions
  • Insiders Transactions Disclosures
  • Invitations
  • invitations-2
  • Presentations
  • Press Kits
  • Press Releases
  • Regulated Information
  • Results 2024
  • Share Capital Increase
  • Uncategorized

Paiania, April 27, 2026 – Today, Lavipharm S.A. conducted its Annual Analyst Update in accordance with the Company’s Financial Calendar for 2026. The presentation took place at the Athens Stock Exchange and was organized by the Hellenic Fund and Asset Management Association. In his opening remarks,...

Flash Note: Annual Financial Results 2025 (Unaudited Financial Data) Strong EBITDA Growth of 48.9% and Significant Increase in Earnings Before Tax by 108,2% Paiania, March 19, 2026 - Lavipharm S.A. informs the investment community of the key financial figures for fiscal year 2025. Consolidated Sales from...

Paiania, 05 March 2026 - Lavipharm S.A., pursuant to articles 4.1.2 & 4.1.3.15.1 of the Athens Stock Exchange Rulebook, announces its Financial Calendar for 2026, as follows.. FINANCIAL CALENDAR 2026...

Peania, November 17, 2025 – Lavipharm S.A. informs the investment community of the Group’s key consolidated financial figures for the nine-month period of 2025. Adjusted Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) from continuing and discontinued operations increased by 11.2%, reaching €10.47 million compared...

Financial Results for the First Half of 2025 – Steady Growth Momentum Peania, September 18, 2025 – Lavipharm Group reports an increase in its consolidated sales during the First Half of 2025. Specifically, consolidated sales from continuing operations amounted to €31.0 million, compared to €29.3 million...

Paiania, 3 July 2025 - Lavipharm S.A. (LAVI) held its Annual General Meeting at the company’s headquarters in Paiania, with a quorum achieved, as 34 shareholders representing 70,34% of the share capital were present. CEO Tilemachos Lavidas opened the session by welcoming shareholders and announcing...

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) Increased by 32.4% Paiania, 15 May 2025 – Lavipharm Group’s total earnings before interest, taxes, depreciation, and amortization (EBITDA) for the First Quarter of 2025 increased by 32.4%, amounting to EUR 3.77 million compared to EUR 2.85 million...

Peania, 23 January 2025 – Lavipharm announces a strategic commercial agreement with the multinational company iNova Pharmaceuticals, the owner of Betadine® and other trusted brands. The new partnership involves the licensing rights of a new antiseptic pharmaceutical OTC product developed by Lavipharm to be commercialized by...